17 Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients

BackgroundThere is limited data on the predictive biomarkers of response to immune checkpoint blockade (ICB) treatment of non-small cell lung cancer (NSCLC) patients. The main aim of this prospective study was to understand the utility of pre-treatment soluble immune checkpoint markers as surrogate...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2021-11, Vol.9 (Suppl 2), p.A19-A19
Main Authors: Raza, Afsheen, Mohsen, Reyad, Kanbour, Aladdin, Zar Gul, Abdul Rehman, Philip, Anite, Vijayakumar, Suma, Hydrose, Shereena, Merhi, Maysaloun, Inchakalody, Varghese, Uddin, Shahab, Homsi, Mohammed Ussama Al, Dermime, Said
Format: Article
Language:English
Subjects:
Biomarkers
Immunotherapy
Lung cancer
Regular and Young Investigator Award Abstracts
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThere is limited data on the predictive biomarkers of response to immune checkpoint blockade (ICB) treatment of non-small cell lung cancer (NSCLC) patients. The main aim of this prospective study was to understand the utility of pre-treatment soluble immune checkpoint markers as surrogate markers for tissue PD-L1 and as predictors of response in locally advanced/metastatic NSCLC patients treated with ICBs.MethodsThe study was conducted at the National Center for Cancer Care and Research (NCCCR), HMC, Qatar. A total of 30 patients on Pembrolizumab/Nivolumab were enrolled and blood samples were collected before treatment. 17 Healthy controls were also included in the study. Multiplex Magnetic Bead Panel kits for soluble immune checkpoint markers was utilized to measure the concentrations of 24 soluble markers including BTLA, GITR, HVEM, IDO, LAG-3, PD-1, PDL-1, PDL-2, TIM-3, CD28, CD80, 4-1BB, CD27, CTLA-4, ICOS Ligand, CD276, VISTA, B7-H6; CD47 (IAP), BLAST-1, Galectin-9, TIMD-4; OX40 and S100A8/A9. Mann-Whitney test was used to evaluate a) the difference in median values between healthy controls and pre-treatment samples b) compare soluble markers with tissue PD-L1 status and c) response to treatment 4 months after treatment via PET CT imaging data.ResultsThe results showed significant changes in the pre-treatment plasma concentrations of soluble markers in the NSCLC patients compared to healthy controls. Significant upregulation was observed in the immune suppression markers: S100A8/A9 (
ISSN:2051-1426
2051-1426
DOI:10.1136/jitc-2021-SITC2021.017